BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sequenta, Inc. Collaborators to Present Five Studies Showing the Power of Lymphosight™ Minimal Residual Disease Platform at European Hematology Association


6/12/2013 9:14:24 AM

STOCKHOLM – Sequenta, Inc. announced today that its collaborators will present studies at the 18th Congress of the European Hematology Association (EHA) here this week demonstrating the superiority of the company’s LymphoSIGHT™ technology in detecting minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and multiple myeloma (MM).

These studies, combined with previous data presented at the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings, show that Sequenta’s LymphoSIGHT platform represents a highly reliable method for detecting MRD in marrow and blood.

“Sequenta’s groundbreaking use of next-generation sequencing to detect and monitor immune cells continues to demonstrate improvements over standard MRD methods across a full range of lymphoid malignancies,” said Tom Willis, Sequenta’s CEO. “The independent validation of the LymphoSIGHT technology by many collaborators has now clearly established our platform as the emerging standard for molecular MRD detection and is the result of the steadfast company commitment to uncompromising, peer-reviewed clinical science.”

Relative to competing platforms, the LymphoSIGHT method offers significant advantages in sensitivity and reproducibility across patients, as well as the ability to follow heterogeneous cancers, including those that have significant rates of mutation before and after diagnosis. All of these technical features translate into a superior ability to predict ultimate relapse.

Earlier this year Sequenta launched its ClonoSIGHT™ test through its CLIA certified facility in South San Francisco. The ClonoSIGHT test utilizes the LymphoSIGHT platform and is the first clinically actionable sequencing-based MRD test. The studies being presented at EHA are:

A COMPARATIVE ANALYSIS OF NEXT-GENERATION SEQUENCING AND REAL-TIME QUANTITATIVE PCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN FOLLICULAR LYMPHOMA

Abstract code: P291

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT-GENERATION SEQUENCING AND REAL-TIME QUANTITATIVE PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM

Abstract code: P293

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

PROGNOSTIC VALUE OF DEEP SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA

Abstract code: P237

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA

Abstract code: P235

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

COMPARISON OF NEXT-GENERATION SEQUENCING AND ASO-PCR METHODS FOR MRD DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Abstract code: S537

Date and Time: 6/15/2013 8:30AM

Location: Hall A4/A5

COMPARISON OF NEXT-GENERATION SEQUENCING AND ASO-PCR METHODS FOR MRD DETECTION IN MANTLE CELL LYMPHOMA

Abstract code: P833

Date and Time: 6/15/2013 5:45PM

Location: Poster Hall

About Sequenta, Inc.

Sequenta is a venture backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequenta.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES